Insmed Incorporated (NASDAQ:INSM) is one of the best strong buy healthcare stocks to invest in. Mizuho cut the price target on Insmed Incorporated (NASDAQ:INSM) to $204 from $211 on February 24, maintaining an Outperform rating on the shares. The rating update came after the fiscal Q4 report, with the firm stating that the company offered “highly positive comments” on the Brinsupri launch. Insmed (INSM) Soars After Raising $650 million Insmed Incorporated (NASDAQ:INSM) reported its fiscal Q4 and full yea ...

Core Insights - Artisan Mid Cap Fund's fourth-quarter 2025 performance showed a decline, with Investor Class at -0.44%, Advisor Class at -0.37%, and Institutional Class at -0.35%, compared to -3.70% for the Russell Midcap® Growth Index, indicating relative resilience in a challenging market [1]. Group 1: Fund Performance - The Fund seeks investments in companies with franchise characteristics, strong earnings trajectories, and trading at a discount to estimated private market value [1]. - Continued strength in information technology and health care sectors contributed positively to the Fund's performance during the quarter [1]. Group 2: Insmed Incorporated (NASDAQ:INSM) - Insmed Incorporated specializes in therapies for serious and rare diseases, with a market capitalization of $33.917 billion [2]. - The stock closed at $159.03 per share on February 23, 2026, with a one-month return of -2.22% and a 52-week gain of 105.20% [2]. - Insmed was a top contributor to the Fund's performance in Q4, driven by strong sales of its lead product ARIKAYCE® and the successful launch of Brinsupri™, which generated $28 million in initial sales [3]. Group 3: Hedge Fund Interest - Insmed was held by 74 hedge fund portfolios at the end of Q4, an increase from 73 in the previous quarter, indicating growing interest among institutional investors [4]. - Despite its potential, the company is not among the 30 most popular stocks among hedge funds, with some analysts suggesting that certain AI stocks may offer greater upside potential [4].

Insmed Inc. (NASDAQ:INSM) ranks among billionaire Stanley Druckenmiller’s 10 best stock picks. On January 23, Roth/MKM began coverage of Insmed Inc. (NASDAQ:INSM) with a Buy rating and a $212 price target. The firm pointed to Insmed’s solid position for further upside in 2026, with predictions that the company’s Brinsupri medication will continue to exceed market expectations. Illumina (ILMN) Jumps 24.8% on Earnings Beat Moreover, the firm assigned a 75% probability of success to the company’s Phase 3 EN ...

Economic Indicators - The February Philadelphia business outlook survey unexpectedly rose by 3.7 to a 5-month high of 16.3, surpassing expectations of a decline to 7.5 [1] - Weekly initial unemployment claims fell by 23,000 to a 5-week low of 206,000, indicating a stronger labor market than the anticipated 225,000 [1][3] - The December trade deficit widened more than expected to $70.3 billion, the largest deficit in 5 months, compared to expectations of $55.5 billion [6] Stock Market Performance - Stock indexes closed lower on Thursday, with the S&P 500 down by 0.28%, the Dow Jones down by 0.54%, and the Nasdaq down by 0.41% [6] - Chipmakers and AI-infrastructure stocks faced significant pressure, contributing to the broader market decline [5][14] - Avis Budget Group's stock fell more than 22% after forecasting full-year adjusted EBITDA of $800 million to $1.00 billion, below the consensus of $1.07 billion [15] Corporate Earnings - Over three-quarters of S&P 500 companies have reported earnings, with 74% beating expectations, and S&P earnings growth is expected to rise by 8.4% in Q4 [9] - Booking Holdings reported Q4 adjusted EPS of $48.80, below the consensus of $48.86, leading to a decline of more than 6% in its stock [17] - Deere & Co raised its full-year net income forecast to between $4.5 billion and $5.0 billion, up from a previous forecast of $4.00 billion to $4.75 billion, resulting in a stock increase of more than 11% [18] Geopolitical Factors - Geopolitical risks impacted stocks, with WTI crude oil rising more than 1% to a 6.5-month high due to concerns over Iran's nuclear negotiations amid U.S. military buildup in the Middle East [4]

Management attributed the exceptional 2025 performance to the 'stunning' early launch of Brinsupri and accelerated global growth of ARIKAYCE, particularly in Japan and Europe. The Brinsupri launch is exceeding internal benchmarks, with $144.6 million in net revenue during its first full quarter, positioning it as potentially the best specialty respiratory launch in history. The strategic focus is on 'owning' the bronchiectasis and NTM categories, leveraging a similar call point among pulmonologists fo ...

Core Insights - Stanley Druckenmiller's Duquesne Family Office made significant portfolio adjustments in Q4 2025, including large positions in financial sector ETFs and a notable exit from Meta [1][2] Group 1: Portfolio Adjustments - In Q4, Druckenmiller opened positions in the Financial Select Sector SPDR ETF (XLF) with 5.4956 million shares, valued at approximately $301 million, making it the second-largest holding in the portfolio at 6.7% of total assets [3] - The Duquesne Family Office also acquired 1.1739 million shares of the Invesco S&P 500 Equal Weight ETF (RSP), valued at about $225 million, representing 5% of the portfolio [4] - Additionally, a new position was taken in the iShares MSCI Brazil ETF (EWZ) with 3.5526 million shares, valued at approximately $113 million, accounting for 2.51% of the portfolio [5] Group 2: Technology Sector Moves - Druckenmiller completely exited his position in Meta Platforms, selling all 76,100 shares, which resulted in a negative exposure change of about 1.38% [6] - Conversely, he significantly increased his stake in Alphabet (GOOGL) by 282,800 shares, a 276.71% increase, bringing the total holding to 385,000 shares valued at around $120 million [7] - The position in Sea Ltd (SE) was also increased by 669,900 shares, a 244.32% rise, with a total holding value of approximately $120 million [8] Group 3: Overall Portfolio Composition - As of the end of Q4 2025, Druckenmiller's portfolio consisted of 62 stocks, with the top five holdings being Natera Inc, Financial Select Sector ETF (XLF), Insmed Inc, S&P 500 Equal Weight ETF (RSP), and Teva Pharmaceutical [8] Group 4: Market Implications - Druckenmiller's trading activities have garnered significant attention on Wall Street, particularly due to his close relationships with key economic decision-makers in the new administration [9] - The potential influence of "Druckenmiller economics," which opposes deficits, inflation, and tariffs, may permeate policy-making through his former associates now in power [10]

科技股方面，德鲁肯米勒Q4清仓了Meta，加仓了谷歌与Sea。德鲁肯米勒与贝森特、沃什的"师徒"关系让市场 推测，"德鲁肯米勒经济学"——即反赤字、反通胀、反关税——可能通过贝森特和沃什渗透至政策制定中。 美东时间2月14日周五美股盘后，递交美国证监会（SEC）的13F文件披露，传奇投资人斯坦利·德鲁 肯米勒（Stanley Druckenmiller）旗下的杜肯家族办公室（Duquesne Family Office）在2025年第四 季度进行了大规模调仓。 Q4，德鲁肯米勒"精准"开仓了金融板块ETF（XLF）、标普500等权重ETF（RSP）和巴西ETF，同时 清仓了Meta，并继续加仓Alphabet（谷歌）。 这份持仓报告公布之际，正值德鲁肯米勒的两位"门徒"——斯科特·贝森特（Scott Bessent）和凯文· 沃什（Kevin Warsh）正式进入美国经济决策核心层。贝森特已于今年1月就任美国财政部长，而沃什 刚被提名为美联储主席。 "精准"开仓金融ETF、标普等权重ETF和巴西ETF 文件显示，德鲁肯米勒在四季度新进买入道富金融精选行业SPDR ETF（XLF），建仓规模达549.56 万股 ...

Definium Therapeutics, Inc. (NASDAQ:DFTX) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. Jefferies Assigns 65–75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III The third stock on our list of most promising stocks is Definium Therapeutics, Inc. (NASDAQ:DFTX). TheFly reported on January 30 that Jefferies initiated coverage of DFTX with a Buy rating and a $30 price target. The firm highlighted that a single dose of DT120, which ...

科技股分化：清仓Meta，加仓谷歌与Sea 科技股方面，德鲁肯米勒Q4进行了显著的分化操作。 美东时间2月14日周五美股盘后，递交美国证监会（SEC）的13F文件披露，传奇投资人斯坦利·德鲁肯 米勒（Stanley Druckenmiller）旗下的杜肯家族办公室（Duquesne Family Office）在2025年第四季度进行 了大规模调仓。 Q4，德鲁肯米勒"精准"开仓了金融板块ETF（XLF）、标普500等权重ETF（RSP）和巴西ETF，同时清 仓了Meta，并继续加仓Alphabet（谷歌）。 这份持仓报告公布之际，正值德鲁肯米勒的两位"门徒"——斯科特·贝森特（Scott Bessent）和凯文·沃什 （Kevin Warsh）正式进入美国经济决策核心层。贝森特已于今年1月就任美国财政部长，而沃什刚被提 名为美联储主席。 "精准"开仓金融ETF、标普等权重ETF和巴西ETF 文件显示，德鲁肯米勒在四季度新进买入道富金融精选行业SPDR ETF（XLF），建仓规模达549.56万 股，期末持仓市值约3.01亿美元。这一举动使XLF直接成为其组合中的第二大重仓标的，占总资产权重 的6.7%。 与 ...

Core Insights - First Turn Management sold its entire stake of 313,733 shares in Arcellx for approximately $25.76 million, as disclosed in an SEC filing on February 13, 2026 [1][2] Company Overview - Arcellx is a clinical-stage biotechnology company focused on developing novel cell-based immunotherapies for cancer treatment, with a diversified pipeline targeting hematologic malignancies and solid tumors [5] - The company has a market capitalization of $3.96 billion, with a revenue of $35.90 million and a net income of -$217.90 million for the trailing twelve months (TTM) [4] Financial Performance - As of February 13, 2026, Arcellx shares were priced at $68.50, reflecting a 7.5% increase over the past year, although this performance lagged behind the S&P 500 by 4.3 percentage points [7] - The company's stock faced pressure due to competitive concerns, particularly related to CAR-T data from Kelonia Therapeutics [9] Investment Implications - The sale of Arcellx shares by First Turn Management suggests a consolidation of conviction in its portfolio, as the fund holds larger positions in other biotech companies [6] - The performance of Arcellx shares, while not catastrophic, indicates a lack of relative strength necessary for a concentrated, high-risk biotech strategy [7]